Pharmafile Logo

tivantinib

- PMLiVE

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

The deal will give Merck control of VLS-101, an antibody-drug conjugate

Ongoing Virtual Communication between MSLs and Physicians: a Customer Story

Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians.

Impetus Digital

- PMLiVE

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

Positive interim results presented at 2020 ESMO virtual congress

- PMLiVE

Merck signs separate agreements with Seattle Genetics for two cancer drugs

Merck makes a $1bn equity investment in the biotech company

In the precision medicine era, the line between products and services is blurred

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

Blue Latitude Health

- PMLiVE

AZ strengthens Daiichi Sankyo partnership with new ADC deal

Deal for experimental antibody drug conjugate could reach $6bn

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead

- PMLiVE

Boehringer links up with Trutino for cancer R&D

Collaboration agreement will focus on cytokine treatments

- PMLiVE

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer

Improved overall survival when compared to chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links